Grammidin NEO with anesthetic lozenges No. 18

Grammidin NEO with anesthetic lozenges No. 18

A country

Russia
The country of production may vary depending on the batch of goods. Please check with the operator for detailed information when confirming your order.

Active substance

Gramicidin C + Oxybuprocaine + Cetylpyridinium chloride

Compound

Gramicidin C, oxybuprocaine, cetylpyridinium chloride.

pharmachologic effect

Antibacterial combined drug for local use in the oral cavity and pharynx. The drug contains the antibiotic gramicidin C, the local anesthetic oxybuprocaine and the antiseptic cetylpyridinium chloride. The drug has a pronounced antibacterial effect against pathogens of infectious and inflammatory diseases of the pharynx and oral cavity. Increases the permeability of the microbial cell membrane, which disrupts its barrier functions and leads to its death. The anesthetic oxybuprocaine, causing a reversible block of axonal conduction of nerve impulses, has an analgesic effect on the mucous membrane of the oral cavity and pharynx. Cetylpyridinium chloride, being an antiseptic, inhibits the growth and reproduction of pathogens of infectious diseases of the oral cavity. The drug has antimicrobial, analgesic and anti-inflammatory effects, reduces discomfort in the oral cavity and pharynx, and facilitates the swallowing process. When absorbed, the drug stimulates hypersalivation, which promotes mechanical cleansing of the oral cavity and pharynx from microorganisms. The drug has a local effect.

Indications for use

Infectious and inflammatory diseases of the oral cavity and pharynx: sore throat, pharyngitis, tonsillitis, periodontal disease, gingivitis, stomatitis.

Mode of application

For adults and children over 12 years of age, the drug is prescribed 1 tablet 3-4 times a day; children aged 4 to 12 years - 1 tablet 1-2 times a day. The tablets are used after meals, dissolving in the mouth without chewing. Immediately after using the drug, you should refrain from eating and drinking for 1-2 hours. If there is no therapeutic effect within 7 days of taking the drug, the patient should consult a doctor.

Interaction

The drug, when taken together, increases the effectiveness of other antimicrobial agents of local and systemic action.

Side effect

In some cases: allergic reactions, temporary loss of sensitivity of the tongue.

Contraindications

I trimester of pregnancy, children under 4 years of age, hypersensitivity to the components of the drug.

Overdose

No data.

special instructions

No data.

Buy Grammidin neo with anesthetic lozenges No. 18 in pharmacies

Grammidin with anesthetic neo Buy Grammidin with anesthetic neo in pharmacies DOSAGE FORMS lozenges 3mg+0 2mg+1mg

MANUFACTURERS Valenta Pharmaceuticals (Russia)

GROUP Combined antibiotics

COMPOSITION Gramicidin C, oxybuprocaine, cetylpyridinium chloride.

INTERNATIONAL NON-PROPENTED NAME Gramicidin C + Oxybuprocaine + Cetylpyridinium chloride

PHARMACOLOGICAL ACTION Antibacterial combined drug for local use in the oral cavity and pharynx. The drug contains the antibiotic gramicidin C, the local anesthetic oxybuprocaine and the antiseptic cetylpyridinium chloride. The drug has a pronounced antibacterial effect against pathogens of infectious and inflammatory diseases of the pharynx and oral cavity. Increases the permeability of the microbial cell membrane, which disrupts its barrier functions and leads to its death. The anesthetic oxybuprocaine, causing a reversible block of axonal conduction of nerve impulses, has an analgesic effect on the mucous membrane of the oral cavity and pharynx. Cetylpyridinium chloride, being an antiseptic, inhibits the growth and reproduction of pathogens of infectious diseases of the oral cavity. The drug has antimicrobial, analgesic and anti-inflammatory effects, reduces discomfort in the oral cavity and pharynx, and facilitates the swallowing process. When absorbed, the drug stimulates hypersalivation, which promotes mechanical cleansing of the oral cavity and pharynx from microorganisms. The drug has a local effect.

INDICATIONS FOR USE Infectious and inflammatory diseases of the oral cavity and pharynx: sore throat, pharyngitis, tonsillitis, periodontal disease, gingivitis, stomatitis.

CONTRAINDICATIONS First trimester of pregnancy, children under 4 years of age, hypersensitivity to the components of the drug.

SIDE EFFECTS In some cases: allergic reactions, temporary loss of sensitivity of the tongue.

INTERACTION The drug, when taken together, increases the effectiveness of other antimicrobial agents of local and systemic action.

METHOD OF APPLICATION AND DOSAGE For adults and children over 12 years of age, the drug is prescribed 1 tablet 3-4 times a day; children aged 4 to 12 years - 1 tablet 1-2 times a day. The tablets are used after meals, dissolving in the mouth without chewing. Immediately after using the drug, you should refrain from eating and drinking for 1-2 hours. If there is no therapeutic effect within 7 days of taking the drug, the patient should consult a doctor.

OVERDOSE No data available.

SPECIAL INSTRUCTIONS No data available.

STORAGE CONDITIONS Store out of reach of children, in a dry place, protected from light at a temperature not exceeding 25 degrees. WITH.

Compound

Analogs

Level 4 ATC code matches: Grammidin for children
Grammidin with anesthetic

Grammidin Neo

Grammidin

Bioparox

Gramicidin S

Trachisan

Among the analogues produced by Valenta Pharmaceuticals are:

• Grammidin Neo (no oxybuprocaine );
• Grammidin with anesthetic ( oxybuprocaine replaced with lidocaine );
• Grammidin (contains only one active component - gramicidin C ).

Pharmacodynamics

A combined drug for the treatment of infectious and inflammatory diseases of the throat and oral cavity. The drug contains the antimicrobial agent gramicidin C, the local anesthetic (painkiller) oxybuprocaine and the antiseptic agent cetylpyridinium chloride.

The mechanism of action of gramicidin C is associated with an increase in the permeability of the cytoplasmic membrane of the microbial cell, which disrupts its stability and causes death.

Gramicidin C has a pronounced antimicrobial effect against pathogens of infectious diseases of the oral cavity and pharynx.

The anesthetic oxybuprocaine has a local anesthetic effect on the mucous membrane of the mouth and throat. Causes a reversible blockade of the propagation and conduction of nerve impulses through the axons of nerve cells.

Cetylpyridinium chloride is an antiseptic. Suppresses the growth and reproduction of pathogens of infectious diseases of the oral cavity.

The drug has an analgesic effect, reduces inflammation, has an antimicrobial effect, softens discomfort in the throat, facilitates swallowing, and when absorbed causes hypersalivation, which contributes to the mechanical cleansing of the oral cavity and pharynx from microorganisms.

Pharmacodynamics and pharmacokinetics

The combined drug includes an antimicrobial component - gramicidin C , an antiseptic - cetylpyridinium chloride and a local anesthetic - oxybuprocaine , which gives an analgesic effect and the drug, in general, is effective for infectious and inflammatory diseases of the oropharynx.

of gramicidin C based on its ability to increase the permeability of the cytoplasmic membranes of microbial cells, causing a violation of the resistance and death of microorganisms (most Gram+ and Gram-).

As a local anesthetic , oxybuprocaine anesthetizes locally on the mucous membrane of the mouth and throat - it acts by reversibly blocking the conduction of nerve signals through the axons (long processes) of nerve cells.

Cetylpyridinium chloride is an antiseptic that inhibits the reproduction and growth of pathogens that cause infectious and inflammatory processes in the mouth and throat.

Thanks to the analgesic effect and antimicrobial effect, inflammation is relieved, discomfort when swallowing is mitigated, and increased salivation promotes natural mechanical cleansing of the throat and oral cavity.

Pharmacokinetics

The drug acts locally, is practically not absorbed from the gastrointestinal tract and does not produce systemic effects.

Grammidin with Anesthetic Neo tablets d/rassas No. 18

Compound

Active substances:

Excipients: colloidal silicon dioxide - 5 mg, talc - 60 mg, acesulfame potassium - 15 mg, mint flavor - 25 mg, sorbitol - 1065.55 mg, magnesium stearate - 25 mg.

Indications for use

Infectious and inflammatory diseases of the mouth and throat: sore throat, pharyngitis, tonsillitis, periodontal disease, gingivitis, stomatitis.

Contraindications

• Hypersensitivity to the components included in the drug;
• children under 4 years of age;
• pregnancy (first trimester).

Directions for use and doses

It is used after meals, by dissolving in the mouth without chewing.

Immediately after using the drug, you should refrain from eating and drinking for 1-2 hours.

Dosage for adults and children over 12 years of age: 1 tablet 3-4 times a day.

Dosage for children from 4 to 12 years: 1 tablet 1-2 times a day.

If there is no therapeutic effect within 7 days of taking the drug, it is recommended to consult a doctor.

Storage conditions

In a place protected from light at a temperature not exceeding 25° C. Keep out of the reach of children.

Best before date

2 years. Do not use after expiration date

special instructions

If there is no therapeutic effect within 7 days, the patient should consult a doctor.

Description

Antibiotic + antiseptic + local anesthetic.

Use in children

Contraindication: children under 4 years of age.

Pharmacodynamics

Combined drug for the treatment of infectious and inflammatory diseases of the pharynx and oral cavity. The drug contains the antimicrobial agent gramicidin C, the local anesthetic agent oxybuprocaine and the antiseptic agent cetylpyridinium chloride.

The mechanism of action of gramicidin C is associated with an increase in the permeability of the cytoplasmic membrane of the microbial cell, which disrupts its stability and causes cell death.

Gramicidin C has a pronounced antimicrobial effect against pathogens of infectious diseases of the oral cavity and pharynx.

The anesthetic oxybuprocaine has a local anesthetic effect on the mucous membrane of the oral cavity and pharynx. Causes a reversible blockade of the propagation and conduction of nerve impulses through the axons of nerve cells.

Cetylpyridinium chloride is an antiseptic. Suppresses the growth and reproduction of pathogens of infectious diseases of the oral cavity.

The drug has an analgesic effect, reduces inflammation, has an antimicrobial effect, softens discomfort in the throat, facilitates swallowing, and when absorbed causes hypersalivation, which contributes to the mechanical cleansing of the oral cavity and pharynx from microorganisms.

Side effects

In some cases: allergic reactions, temporary loss of sensitivity of the tongue.

Use during pregnancy and breastfeeding

It is not recommended to use the drug during pregnancy (I) trimester. Breastfeeding should be stopped while taking the drug.

Interaction

Grammidin® with neo anesthetic enhances the effects of other antimicrobial agents of local and systemic action.